

First North Announcement no. 6 2007/ 27th April, 2007

Copenhagen, 27th April, 2007

Summary: Quarterly Announcement – Aresa has begun the first growth trials and new test sites are being prepared for use.

Quarterly Announcement, 1st Quarter 2007

The plant biotech company Aresa has used the first months of the year to prepare the multitude of seeding and growth tests that are planned for the growth season 2007.

Aresa has entered into a collaboration with the Danish Defence for the use of a 3.000m² test field at their site in Jægerspris. This site is to substitute the previous test site at Amager. The new test site in Jægerspris is being established and gives Aresa a larger and better area for testing in 2007 and beyond.

The first growth tests have been initiated and activities will continue throughout the growing season 2007.

Aresa has, during the first quarter, applied for GMO approval for testing in both Denmark and in Bosnia-Herzegovina. The process in Denmark is ongoing and an approval is expected soon. In Bosnia-Herzegovina, Aresa has received a rejection of the GMO application and as a consequence of this, initial discussion has been initiated with the neighbouring country Serbia to establish a test area there. Serbia has since 2001 had GMO legislation in place and the necessary formal structures therefore exists to properly deal with GMO applications.

On the 21st March Aresa received notification that the patent authorities in South Africa and in Singapore had granted a patent in respect of "Reporter system for plants", patent No. 2004/9782 in South Africa and patent No. 108113 in Singapore (see First North announcement No. 5 2007).

Aresa's first General Assembly, after the introduction on First North, was held on the 15th March. The Supervisory Board was re-elected and the Annual Report for 2006 was approved.

First North Announcement No. 6 2007 /27th April 2007

The unaudited financial figures for the period 1st January to 31st March 2007 are as follows:

(amounts in '000 DKK)	1/1 – 31/3 2007	1/1 – 31/3 2006
Net turnover	0	0
Result of Operations	-3,837	-2,130
Financials, net	297	143
Result before tax	-3,540	-1,987

(amounts in '000 DKK)	1/1 – 30/9 2006	1/1 – 30/9 2005
Assets, total	51,543	64,445
Equity, total	49,464	62,791

Development of equity ('000 DKK):

Equity 1/1 2007:	53,004
Net result first quarter	<u>-3.540</u>
Equity 31/3 2007:	49,464

For the full year a negative net result of DKK 14-17 million is expected, which is in accordance with previously communicated expectations.

Best regards,
Jarne Elleholm
CEO
Aresa A/S

Further information can be obtained by contacting Jarne Elleholm, CEO for Aresa A/S on +45 70227747, mobile: +45 41190136 or to the company's financial advisor HSH Gudme Corporate Finance A/S, Morten Kjærulff, Director, +45 33449431.

About Aresa

Aresa is a plant biotech company established in 2001 by the company's current CSO, Carsten Meier and has origins from the Institute of Molecular Biology at Copenhagen University.

Aresa has developed two plant based technology platforms, BioSensor for the detection of substances in soil, hereunder evaporation of explosives from landmines; and BioPharma, a tool for the optimisation and production of antibodies and proteins in plants.

Aresa was listed on the Copenhagen OMX-First North market place in 2006. Aresa is based at Symbion Science Park in Copenhagen and has greenhouse facilities in the outskirts of Copenhagen and test areas in Denmark, Croatia and in Bosnia Herzegovina. Aresa has 17 employees, hereof 9 within research and development and 5 within landmine operations.

First North Announcement No. 6 2007 /27th April 2007